newsfilter
← Latest News
GlobeNewswire·

Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

  • Ligand Pharmaceuticals CEO Todd Davis & CFO Tavo Espinoza will attend the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026.
  • Executives will participate in a fireside chat at 10:00 a.m. Eastern Time & host one-on-one investor meetings during the event.
  • Ligand operates a low-cost, infrastructure-light business model focused on financing, licensing, & royalty rights in mid- to late-stage drug development.
  • The company utilizes two IP platforms: Captisol® for optimizing drug solubility & stability & NITRICIL™ for tunable dosing & adjustable release profiles.
  • Ligand maintains alliances with major pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences, & Baxter International.
  • The company discloses material non-public information via its investor relations website & X account to comply with Regulation FD.